CONTINUOUS IMPROVEMENT OF SKIN AGING APPEARANCE THROUGH A NEW FACIAL SERUM
213
Presented by: Zhiming (Jimmy) ZHANG
Background:
Skin aging is in part characterized by loss of moisture, elasticity and firmness, rough texture, as well as skin tone dullness, which finally lead to the formation of fine lines and wrinkles. A typical clinical study for an anti-aging cosmetical product is no more than three months with only one targeted age group, which presents limitation to evaluate long term benefits as well as treatment response for different age groups.
Objective:
To fill this gap, a one-year clinical study, based on three age groups of 20-50 y.o subjects was designed to evaluate the efficacy and tolerance of a newly developed multi-benefit facial serum containing bifida ferment lysate, sphingomonas ferment extract, salicyloyl phytosphingosine, hydroxyethylpiperazine ethane sulfonic acid and papain.
Methods:
An open-label, single center clinical study was initiated, in which three age groups (Group 1: 20-29 years old, Group 2: 30-39 years old, Group 3: 40-50 years old) of Chinese women were recruited. Each age group contains ~70 volunteers, who presented with mild to moderate signs of photoaging, with a total of 222 volunteers enrolled. After a 3-week washout period, subjects were instructed to apply the investigational serum on full face twice a day in the morning and evening for 1 year, from Dec 25th, 2020 to Dec 29th ,2021. Subjects were seen at baseline, 1 month, 2 months, 3 months, 9 months, and 12 months after the first application. Clinical grading with a scale of 0-9 was performed on skin radiance, translucency, brightness, smoothness, softness, elasticity and firmness for all three age groups. In addition, age-specific attributes, for example, skin evenness, skin plumpness, and cheek pores were evaluated for subjects in Group1; underneath eye wrinkles and global appearance of fine lines were evaluated for subjects in Group2; global appearance of fine lines, global wrinkles and crow’s feet wrinkles were evaluated for subjects in Group3. Subject self-assessment questionnaire along with standardized photographs were taken at each visit for all the subjects.
Results:
So far, 182 subjects completed the 9-month clinical evaluation, with a projection of >170 subjects completing the whole study. For all the subjects, compare to clinical grading conducted at baseline, statistically significant (p < 0.05) improvement in skin radiance was observed with an improvement rate of 10.40%, 10.89%, 12.61% and 24.76% at 1, 2, 3, and 9 months, respectively. Similarly, significant improvement (p< 0.05) in clinical grading of skin smoothness was also noticed, with an improvement rate of 7.44%, 10.64%, 10.67%, and 33.64% at 1, 2, 3, and 9 months, respectively, compared to baseline. Besides, based on clinical grading, significantly improved efficacy (p< 0.05) in other skin attributes, including skin translucency, brightness, softness, elasticity and firmness, were also observed for all tested subjects compared to baseline since 1-month application. Focusing on each age group, significantly better performance (p< 0.05) based on clinical grading on cheek pore (12.85%), skin evenness (22.52%) and skin plumping (34.80%) was seen in Group1, reduction of fine lines (51.4%) was seen in Group2, and reduction of wrinkles (25.48%) was seen in Group3 after long-term use (till 9 months so far), which were consistent with the favorable ratings from the self-assessment questionnaire. In addition, the investigational serum was well tolerated without any adverse event reported.
Conclusion:
The results suggest that this newly developed facial serum can continuously improve skin aging appearance over time with twice daily usage. Strong efficacy in improving age-specific skin attributes can also be delivered through the investigational product.
Skin aging is in part characterized by loss of moisture, elasticity and firmness, rough texture, as well as skin tone dullness, which finally lead to the formation of fine lines and wrinkles. A typical clinical study for an anti-aging cosmetical product is no more than three months with only one targeted age group, which presents limitation to evaluate long term benefits as well as treatment response for different age groups.
Objective:
To fill this gap, a one-year clinical study, based on three age groups of 20-50 y.o subjects was designed to evaluate the efficacy and tolerance of a newly developed multi-benefit facial serum containing bifida ferment lysate, sphingomonas ferment extract, salicyloyl phytosphingosine, hydroxyethylpiperazine ethane sulfonic acid and papain.
Methods:
An open-label, single center clinical study was initiated, in which three age groups (Group 1: 20-29 years old, Group 2: 30-39 years old, Group 3: 40-50 years old) of Chinese women were recruited. Each age group contains ~70 volunteers, who presented with mild to moderate signs of photoaging, with a total of 222 volunteers enrolled. After a 3-week washout period, subjects were instructed to apply the investigational serum on full face twice a day in the morning and evening for 1 year, from Dec 25th, 2020 to Dec 29th ,2021. Subjects were seen at baseline, 1 month, 2 months, 3 months, 9 months, and 12 months after the first application. Clinical grading with a scale of 0-9 was performed on skin radiance, translucency, brightness, smoothness, softness, elasticity and firmness for all three age groups. In addition, age-specific attributes, for example, skin evenness, skin plumpness, and cheek pores were evaluated for subjects in Group1; underneath eye wrinkles and global appearance of fine lines were evaluated for subjects in Group2; global appearance of fine lines, global wrinkles and crow’s feet wrinkles were evaluated for subjects in Group3. Subject self-assessment questionnaire along with standardized photographs were taken at each visit for all the subjects.
Results:
So far, 182 subjects completed the 9-month clinical evaluation, with a projection of >170 subjects completing the whole study. For all the subjects, compare to clinical grading conducted at baseline, statistically significant (p < 0.05) improvement in skin radiance was observed with an improvement rate of 10.40%, 10.89%, 12.61% and 24.76% at 1, 2, 3, and 9 months, respectively. Similarly, significant improvement (p< 0.05) in clinical grading of skin smoothness was also noticed, with an improvement rate of 7.44%, 10.64%, 10.67%, and 33.64% at 1, 2, 3, and 9 months, respectively, compared to baseline. Besides, based on clinical grading, significantly improved efficacy (p< 0.05) in other skin attributes, including skin translucency, brightness, softness, elasticity and firmness, were also observed for all tested subjects compared to baseline since 1-month application. Focusing on each age group, significantly better performance (p< 0.05) based on clinical grading on cheek pore (12.85%), skin evenness (22.52%) and skin plumping (34.80%) was seen in Group1, reduction of fine lines (51.4%) was seen in Group2, and reduction of wrinkles (25.48%) was seen in Group3 after long-term use (till 9 months so far), which were consistent with the favorable ratings from the self-assessment questionnaire. In addition, the investigational serum was well tolerated without any adverse event reported.
Conclusion:
The results suggest that this newly developed facial serum can continuously improve skin aging appearance over time with twice daily usage. Strong efficacy in improving age-specific skin attributes can also be delivered through the investigational product.